The UA1MG level was tested using the overnight clean midstream urine, which was sampled in the morning between 6: 00 a.m. and 11: 00 a.m., within 24 h of hospital admission, and sent to the Laboratory Medicine Department within 1 h for testing, as previously reported [9 (link)]. The nephelometry assay kit was used to test the UA1MG level with the BN II protein analyzer (Siemens, Germany), with a normal reference range provided by the manufacturer of 0.0 to 1.2 mg/dL. As previously described [7 (link)], patients had their peripheral blood draw sampled immediately on admission. Complete blood cell counts were measured using the fluorescent dyeing flowcytometry method with the XN3000 analyzer (Sysmex, Japan). The lipid panel, glycated hemoglobin A1c, and high-sensitivity C-reactive protein (hs-CRP) levels were collected on the morning of the second day after at least 8 h of fasting. The levels of cardiac enzymes involving troponin I (cTnI), creatine kinase myocardial band (CK-MB), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were collected on admission and every morning according to the hospital protocol. Blood biochemistry parameters and cardiac biomarkers were evaluated using test kits with AU5821 biochemistry analyzing equipment (Beckman Coulter Company), according to the manufacturer’s instructions.